ERC Belgium Submits Marketing Authorization Application to European Medicines Agency (EMA) for Glioblastoma Immunotherapy, SITOIGANAP
Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)
This is great news for Europe. This vaccine was shown to be very safe, and early results show that it helps some patients, with more than 10 % of recurrent GBM patients survived over 3 years which is pretty good. They are applying for a conditional approval in Europe. Here in the USA we do not have conditional approvals yet and it will take another few years to make this available in the USA. I am working on a bill that would allow the conditional pathway to be used here in the USA. I will write a news blast about it in a few days!
Posted on: 06/27/2020
Click HERE to return to brain tumor news headlines